Free CME from PeerView


Gynecology/Obstetrics CME

Reshma L. Mahtani, DO
Credits: 1.0 CME / MOC / NCPD / IPCE
PVI, PeerView Institute for Medical Education
A Clinical Compass for Selecting and Sequencing HER2-Targeting Therapies in HER2-Positive Metastatic Breast Cancer: An Update on the Latest Evidence, Guidelines, and Expert Insights
March 05, 2024
Erika Hamilton, MD
Credits: 1.0 CME / MOC / NCPD / CPE / AAPA / IPCE
PVI, PeerView Institute for Medical Education
Simplifying the Complicated: An Algorithmic Guide for Clinical Decision-Making in HR+, HER2- EBC and MBC
January 18, 2024
Joyce O’Shaughnessy, MD
Credits: 1.0 CME / MOC / NCPD / CPE / AAPA / IPCE
PVI, PeerView Institute for Medical Education
Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBC
January 10, 2024
Credits: 0.5 CME / MOC / AAPA / IPCE
PVI, PeerView Institute for Medical Education
The ABCs of ADCs for Gynecologic Cancer: Expert Insights on Effective Implementation and Practical Tips for Use in Patients With Cervical, Ovarian, or Endometrial Cancer
December 11, 2023
Erika Hamilton, MD
Credits: 1.5 CME / MOC / AAPA
PVI, PeerView Institute for Medical Education
Mastering the Art of Precision in the Treatment of HR+ Early and Metastatic Breast Cancer: Risk Assessment, Prognostic Testing, and Selection and Sequencing of Therapies
December 07, 2023
Sara A. Hurvitz, MD, FACP
Credits: 1.5 CME / MOC / AAPA
PVI, PeerView Institute for Medical Education
Modern Practice Principles: A Practical “How-To” Guide for Selection, Sequencing, and Optimal Use of HER2-Targeted Therapies in HER2-Positive Breast Cancer
December 06, 2023
Credits: 1.0 CME / MOC / AAPA
PVI, PeerView Institute for Medical Education
Revolutionizing Solid Tumor Treatment, Unleashing the Potential of Antibody–Drug Conjugates: How to Make the Most of the Latest Clinical Evidence to Enhance Patient Care
November 13, 2023
Credits: 1.5 CME / NCPD / CPE / AAPA
PVI, PeerView Institute for Medical Education
Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care
November 09, 2023
Credits: 1.5 CME / MOC / AAPA
PVI, PeerView Institute for Medical Education
Endometrial Cancer Care in the Age of Immunotherapy: Translating Clinical Evidence Into Meaningful Improvements in Patient Outcomes Across the Disease Continuum
June 03, 2023
Credits: 0.75 CME / MOC
PVI, PeerView Institute for Medical Education
Upgrading the Treatment Algorithm for Advanced Ovarian Cancer: Expert Tips, Tools, and Patient Care Strategies for Making the Most of PARP Inhibitors Across the Disease Continuum
May 15, 2023
Credits: 1.5 CME / NCPD / ILNA / IPCE
PVI, PeerView Institute for Medical Education
Expert Nursing Insights on Personalized Care for Gynecologic Cancers: Educating and Supporting Patients on the Latest Therapeutic Approaches
April 25, 2023
Credits: 1.0 CME / MOC
PVI, PeerView Institute for Medical Education
Immunotherapy as a Treatment Cornerstone for Advanced Endometrial Cancer: Personalizing Patient Care
March 24, 2023
Credits: 1.0 CME / MOC
PVI, PeerView Institute for Medical Education
Navigating Complex Decisions at the Intersection of Local and Systemic Management of Early Breast Cancer
March 23, 2023
PVI, PeerView Institute for Medical Education
Refining Best Practices in Cancer Immunotherapy Biomarker Testing and Pathologic Response Assessment
March 01, 2023
PVI, PeerView Institute for Medical Education
New Horizons for Advanced Endometrial Cancer Treatment: Utilizing Innovative Immunotherapies and Other Novel Approaches
February 06, 2023
PVI, PeerView Institute for Medical Education
Clarifying the Complexities of the Expanding Treatment Options for Advanced- and Early-Stage HR+/HER2- Breast Cancer
December 06, 2022
Medical Learning Institute, Inc.
Making Sense of the Evolving Treatment Landscape in Ovarian Cancer Care: Pharmacy Perspectives on PARP Inhibitor Therapy
May 06, 2022
PVI, PeerView Institute for Medical Education
Parsing the Practicalities of Pathologic Response Assessment After Neoadjuvant Immunotherapy to Facilitate Progress in Early-Stage Cancers
April 09, 2022

Pages